Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-28T03:36:13.442Z Has data issue: false hasContentIssue false
  • English
  • Français

Clomipramine versus Phenelzine in Obsessive–Compulsive Disorder

A Controlled Clinical Trial

Published online by Cambridge University Press:  02 January 2018

J. Vallejo ,
J. Olivares ,
T. Marcos ,
A. Bulbena  and
J. M. Menchón
J. Vallejo*
Affiliation:
Hospital de Prínceps d'Espanya
J. Olivares
Affiliation:
Hospital Clinic i Provincial, Barcelona
T. Marcos
Affiliation:
Department of Psychiatry, Hospital Clínic i Provincial, Barcelona
A. Bulbena
Affiliation:
Hospital del Mar, Barcelona, and Professor of Psychiatry, University of País Vasco, Barcelona
J. M. Menchón
Affiliation:
Hospital de Prínceps d'Espanya, Ciutat Sanitaria i Universitària de Bellvitge, Barcelona, Spain
*
∗Hospital de Bellvitge, Servicio de Psiquiatria, Feixa Llarga s/n, 08907 Hospitalet de Llobregat (Barcelona), Spain
Get access Rights & Permissions [Opens in a new window]

Abstract

A double-blind clinical trial of clomipramine versus phenelzine was carried out on 30 patients suffering from DSM–III obsessive–compulsive disorder. The study period was 12 weeks, and the maximum doses used (from the fifth week on) were 225 mg/day for clomipramine (14 patients) and 75 mg/day for phenelzine (12 patients); four patients dropped out. Obsessive symptoms improved significantly in both drug groups, but there was no significant difference between groups. Depressive symptoms improved before obsessive ones.

Type
Papers
Information
The British Journal of Psychiatry , Volume 161 , Issue 5 , November 1992 , pp. 665 - 670
Copyright
Copyright © 1992 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allen, J. J. & Tune, G. S. (1975) The Lynfield obsessive–compulsive questionnaire. Scottish Medical Journal, 20, 21–26.CrossRefGoogle Scholar
American Psychiatric Association (1960) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Ananth, J., Pecknold, J, van den Steen, N., et al (1979) Double-blind comparative study of chtorimipramine in obsessive neurosis. Current Therapeutic Research, 25, 703–709.Google Scholar
Carroll, B. J., Feinberg, M., Greden, J., et al (1981) A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility. Archives of General Psychiatry, 38, 15–22.Google Scholar
Eysenck, H. J. & Eysenck, S. B. G. (1964) Manual of the Eysenck Personality Inventory. London: University of London Press.Google Scholar
Flament, M., Rapoport, J., Berg, C., et al (1985) Clomipramine treatment of childhood obsessive–compulsive disorder. Archives of General Psychiatry, 42, 977–983.CrossRefGoogle ScholarPubMed
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.Google Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.Google Scholar
Insel, T., Murphy, D., Cohen, R., et al (1983) Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry, 40, 605–612.CrossRefGoogle ScholarPubMed
Insel, T., Mueller, E., Alterman, I., et al (1985) Obsessive-compulsive disorder and serotonin: is there a connection? Biological Psychiatry, 20, 1174–1188.CrossRefGoogle ScholarPubMed
Isberg, R. (1981) A comparison of phenelzine and imipramine in an obsessive–compulsive patient. American Journal of Psychiatry, 138, 1250–1251.Google Scholar
Jaskari, M. (1980) Observations on mianserin in the treatment of obsessive neurosis. Current Medical Research Opinion, 6 (suppl. 7): 128–131.CrossRefGoogle Scholar
Jenike, M. (1981) Rapid response of severe obsessive-compulsive disorder to tranylcypromine. American Journal of Psychiatry, 138, 1249–1250.Google ScholarPubMed
Jenike, M., Surman, O., Cassem, N., et al (1983) Monoamine oxidase inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry, 44, 131–132.Google Scholar
Joel, S. (1959) Twenty-month study of iproniazid therapy. Diseases of the Nervous System, 20, 1–4.Google Scholar
Lowenthal, M. & Haven, C. (1968) Interaction and adaptation: intimacy as a critical variable. American Sociological Review, 33, 20–30.CrossRefGoogle ScholarPubMed
Marks, I., Stern, R., Mawson, D., et al (1980) Clomipramine and exposure for obsessive-compulsive rituals: I. British Journal of Psychiatry, 136, 1–25.Google Scholar
Marks, I., Lelliot, P., Basoglu, M., et al (1988) Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive ritual. British Journal of Psychiatry, 152, 522–534.Google Scholar
Mavissakalian, M. & Michelson, L. (1983) Tricyclic antidepressants in obsessive-compulsive disorder. Antiobsessional or antidepressant agents? Journal of Nervous and Mental Disease, 171, 301–306.Google Scholar
Mavissakalian, M., Turner, S., Michelson, L., et al (1985) Tricyclic antidepressants in obsessive–compulsive disorder antiobsessional or antidepressant agents? II. American Journal of Psychiatry, 142, 572–576.Google ScholarPubMed
Medalie, J. & Goldbourt, V. (1976) Angina pectoris among 10,000 men. II. Psychosocial and other risk factors as evidenced by a multivariate analysis of a five-year incidence study. American Journal of Medicine, 60, 910–921.CrossRefGoogle Scholar
Montgomery, S. (1980) Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmacological Medicine, 1, 189–192.Google Scholar
Murphy, D. L., Aulakh, C. S., Garrick, N. A., et al (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In Psychopharmacology – The Third Generation of Progress (ed. H. Y. Meltzer), pp. 545–552. New York: Raven Press.Google Scholar
Philpott, R. (1975) Recent advances in the behavioural measurement of obsessional illness: difficulties common to these and other measures. Scottish Medical Journal, 20, 33–39.CrossRefGoogle ScholarPubMed
Rachman, S. & Hodgson, R. J. (1980) Obsessions and Compulsions. New Jersey: Prentice Hall.Google Scholar
Rapoport, J., Elkins, R. & Mikkelson, M. (1980) Clinical controlled trial of chlorimipramine in adolescents with obsessive-compulsive disorder. Psychopharmacological Bulletin, 16, 61–63.Google Scholar
Rihmer, Z., Szantok, S. & Arato, M. (1982) Response of phobic disorders with obsessive symptoms to MAO inhibitors. American Journal of Psychiatry, 139, 1374.Google ScholarPubMed
Sarason, I. (1978) Assessing the impact of life changes: development of the Life Experiences Survey. Journal of Consulting and Clinical Psychology, 46, 926–946.Google Scholar
Swinson, R. (1984) Response to tranylcypromine and thought stopping in obsessional disorder. British Journal of Psychiatry, 144, 425–427.Google Scholar
Thoren, P., Asberg, M., Bertilsson, L., et al (1980) Clomipramine treatment of obsessive-compulsive disorder. II Biochemical aspects. Archives of General Psychiatry, 37, 1289–1294.Google Scholar
Volavska, J., Neizoglu, F. & Yaryura-Tobias, J. (1985) Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Research, 14, 83–91.Google Scholar
Zohar, J. & Insel, T. (1987) Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biological Psychiatry, 22, 667–687.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.